FRAMINGHAM, Mass.--(BUSINESS WIRE)--Aug. 3, 2006--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) reported today its financial results for the second quarter ended July 2, 2006, as well as receipt of the Scientific Advice of the European Medicines Agency, or EMEA, on a planned clinical program to study ATryn(R) as a treatment for disseminated intravascular coagulation, or DIC, associated with severe sepsis.
